On May 4, 2017 GliaCure President Philip Haydon’s laboratory at Tufts University published its findings on the role of astrocytes in schizophrenia in the journal Neuron. N-methyl D-aspartate receptors (NMDARs) play a direct role in many aspects of brain physiology. It is hypothesized that diminished functioning of synaptic NMDAR signaling underlies the etiology of schizophrenia....more »
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »